173 related articles for article (PubMed ID: 36834962)
1. Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines.
Kutyna MM; Loone S; Saunders VA; White DL; Kok CH; Hiwase DK
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834962
[TBL] [Abstract][Full Text] [Related]
2. Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.
Hur EH; Jung SH; Goo BK; Moon J; Choi Y; Choi DR; Chung YJ; Lee JH
Oncotarget; 2017 Feb; 8(7):11748-11762. PubMed ID: 28052028
[TBL] [Abstract][Full Text] [Related]
3. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
4. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells.
Hummel-Eisenbeiss J; Hascher A; Hals PA; Sandvold ML; Müller-Tidow C; Lyko F; Rius M
Mol Pharmacol; 2013 Sep; 84(3):438-50. PubMed ID: 23814180
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia cells MOLM-13 and SKM-1 established for resistance by azacytidine are crossresistant to P-glycoprotein substrates.
Messingerova L; Imrichova D; Kavcova H; Turakova K; Breier A; Sulova Z
Toxicol In Vitro; 2015 Oct; 29(7):1405-15. PubMed ID: 26009263
[TBL] [Abstract][Full Text] [Related]
6. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
7. Silencing HO-1 sensitizes SKM-1 cells to apoptosis induced by low concentration 5-azacytidine through enhancing p16 demethylation.
Wang P; Ma D; Wang J; Fang Q; Gao R; Wu W; Lu T; Cao L
Int J Oncol; 2015 Mar; 46(3):1317-27. PubMed ID: 25585641
[TBL] [Abstract][Full Text] [Related]
8. Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents.
Janotka Ľ; Messingerová L; Šimoničová K; Kavcová H; Elefantová K; Sulová Z; Breier A
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669837
[TBL] [Abstract][Full Text] [Related]
9. Selection of resistant acute myeloid leukemia SKM-1 and MOLM-13 cells by vincristine-, mitoxantrone- and lenalidomide-induced upregulation of P-glycoprotein activity and downregulation of CD33 cell surface exposure.
Imrichova D; Messingerova L; Seres M; Kavcova H; Pavlikova L; Coculova M; Breier A; Sulova Z
Eur J Pharm Sci; 2015 Sep; 77():29-39. PubMed ID: 26002042
[TBL] [Abstract][Full Text] [Related]
10. Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia.
Al-Jamal HA; Mat Jusoh SA; Hassan R; Johan MF
BMC Cancer; 2015 Nov; 15():869. PubMed ID: 26547689
[TBL] [Abstract][Full Text] [Related]
11. Multiomics of azacitidine-treated AML cells reveals variable and convergent targets that remodel the cell-surface proteome.
Leung KK; Nguyen A; Shi T; Tang L; Ni X; Escoubet L; MacBeth KJ; DiMartino J; Wells JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):695-700. PubMed ID: 30584089
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms.
Carter JL; Su Y; Qiao X; Zhao J; Wang G; Howard M; Edwards H; Bao X; Li J; Hüttemann M; Yang J; Taub JW; Ge Y
Biochem Pharmacol; 2023 Oct; 216():115759. PubMed ID: 37604291
[TBL] [Abstract][Full Text] [Related]
13. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
14. BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.
Cluzeau T; Robert G; Mounier N; Karsenti JM; Dufies M; Puissant A; Jacquel A; Renneville A; Preudhomme C; Cassuto JP; Raynaud S; Luciano F; Auberger P
Oncotarget; 2012 Apr; 3(4):490-501. PubMed ID: 22577154
[TBL] [Abstract][Full Text] [Related]
15. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Cluzeau T; Furstoss N; Savy C; El Manaa W; Zerhouni M; Blot L; Calleja A; Dufies M; Dubois A; Ginet C; Mounier N; Garnier G; Raynaud S; Rohrlich PS; Peterlin P; Stamatoullas A; Chermat F; Fenaux P; Jacquel A; Robert G; Auberger P
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881723
[TBL] [Abstract][Full Text] [Related]
16. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
18. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.
Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM
J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188
[TBL] [Abstract][Full Text] [Related]
19. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
20. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
Schmelz K; Wagner M; Dörken B; Tamm I
Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]